A detailed history of Northern Trust Corp transactions in Allogene Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 1,248,539 shares of ALLO stock, worth $2.83 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,248,539
Previous 1,038,105 20.27%
Holding current value
$2.83 Million
Previous $2.42 Million 44.54%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$2.08 - $3.5 $437,702 - $736,519
210,434 Added 20.27%
1,248,539 $3.5 Million
Q2 2024

Aug 14, 2024

BUY
$2.23 - $4.38 $149,494 - $293,626
67,038 Added 6.9%
1,038,105 $2.42 Million
Q1 2024

May 14, 2024

SELL
$2.92 - $5.63 $126,371 - $243,655
-43,278 Reduced 4.27%
971,067 $4.34 Million
Q4 2023

Feb 13, 2024

BUY
$2.28 - $3.5 $350,705 - $538,363
153,818 Added 17.87%
1,014,345 $3.26 Million
Q3 2023

Nov 13, 2023

SELL
$3.17 - $5.96 $6,273 - $11,794
-1,979 Reduced 0.23%
860,527 $2.73 Million
Q2 2023

Aug 11, 2023

BUY
$4.53 - $6.74 $286,898 - $426,864
63,333 Added 7.92%
862,506 $4.29 Million
Q1 2023

May 15, 2023

SELL
$4.92 - $8.21 $153,656 - $256,406
-31,231 Reduced 3.76%
799,173 $3.95 Million
Q4 2022

Feb 13, 2023

SELL
$5.62 - $11.11 $1.88 Million - $3.72 Million
-335,206 Reduced 28.76%
830,404 $5.22 Million
Q3 2022

Nov 14, 2022

BUY
$10.32 - $17.28 $4.27 Million - $7.14 Million
413,301 Added 54.94%
1,165,610 $12.6 Million
Q2 2022

Aug 12, 2022

BUY
$6.78 - $12.28 $360,892 - $653,652
53,229 Added 7.61%
752,309 $8.58 Million
Q1 2022

May 13, 2022

SELL
$7.65 - $15.29 $196,123 - $391,989
-25,637 Reduced 3.54%
699,080 $6.37 Million
Q4 2021

Feb 08, 2022

BUY
$13.13 - $24.52 $147,252 - $274,991
11,215 Added 1.57%
724,717 $10.8 Million
Q3 2021

Nov 15, 2021

SELL
$21.01 - $27.64 $453,647 - $596,802
-21,592 Reduced 2.94%
713,502 $18.3 Million
Q2 2021

Aug 13, 2021

BUY
$23.49 - $35.8 $2.03 Million - $3.1 Million
86,630 Added 13.36%
735,094 $19.2 Million
Q1 2021

May 12, 2021

SELL
$25.79 - $39.02 $519,487 - $785,979
-20,143 Reduced 3.01%
648,464 $22.9 Million
Q4 2020

Feb 11, 2021

SELL
$25.24 - $43.45 $327,615 - $563,981
-12,980 Reduced 1.9%
668,607 $16.9 Million
Q3 2020

Nov 16, 2020

BUY
$32.38 - $44.96 $290,416 - $403,246
8,969 Added 1.33%
681,587 $25.7 Million
Q2 2020

Aug 14, 2020

BUY
$18.39 - $54.04 $2.83 Million - $8.33 Million
154,124 Added 29.73%
672,618 $28.8 Million
Q1 2020

May 14, 2020

BUY
$18.22 - $28.25 $118,047 - $183,031
6,479 Added 1.27%
518,494 $10.1 Million
Q4 2019

Feb 14, 2020

SELL
$24.82 - $31.4 $396,251 - $501,301
-15,965 Reduced 3.02%
512,015 $13.3 Million
Q3 2019

Nov 13, 2019

BUY
$26.11 - $32.99 $5.66 Million - $7.16 Million
216,959 Added 69.76%
527,980 $14.4 Million
Q2 2019

Aug 13, 2019

BUY
$25.56 - $31.09 $536,018 - $651,988
20,971 Added 7.23%
311,021 $8.35 Million
Q1 2019

May 13, 2019

BUY
$24.82 - $32.54 $94,564 - $123,977
3,810 Added 1.33%
290,050 $8.39 Million
Q4 2018

Feb 12, 2019

BUY
$22.5 - $33.3 $6.44 Million - $9.53 Million
286,240 New
286,240 $7.71 Million

Others Institutions Holding ALLO

About Allogene Therapeutics, Inc.


  • Ticker ALLO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 143,807,008
  • Market Cap $326M
  • Description
  • Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...
More about ALLO
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.